You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》瑞信上調國藥控股(01099.HK)目標價至26元 評級「跑贏大市」
阿思達克 03-29 10:47
瑞信發表報告指,在過去兩個月,國藥控股(01099.HK)股價表現明顯地跑贏大市,但未來或有更多上行壓力。該行指,公司去年第四季收入遜於該行預期,而純利則略勝於預期,而去年經營現金流有所改善,大部分主因通過保理計劃終止確認的貿易應收賬款顯著增加,令應收賬款有所改善。 該行預期,醫院人流復甦將推動今年收入增長,基於集團供應鏈及分銷網絡的優勢,管理層有信心銷售增長將高於同業3%至5%。此外,該行相信醫療器械設備及零售藥店業務繼續表現強勁,將有助推動集團收入及毛利率上升。 該行將公司今年及明年每股盈測分別上調5.1%及5.4%,目標價由24元上調至26元,維持評級「跑贏大市」。(ca/k) ~
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account